Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Rides on New Product Suite, Currency Woes Stay
by Zacks Equity Research
Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.
Here's Why You Should Retain Pacific Biosciences Stock Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Here's Why You Should Hold on to Thermo Fisher Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.
The Zacks Analyst Blog Highlights: QUALCOMM, NVIDIA, Charter, Microsoft and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QUALCOMM, NVIDIA, Charter, Microsoft and Thermo Fisher Scientific
5 Corporate Giants That Popped in 2019 and Have Upside Left
by Nalak Das
A stable U.S. economy, a partial trade deal with China, possible solution of Brexit and easy monetary policy of the Fed are likely to sustain Wall Street's rally in 2020.
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
Patterson Companies (PDCO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.
What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Thermo Fisher Rides on New Product Suite and Global Growth
by Urmimala Biswas
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
Top Analyst Reports for Procter & Gamble, Thermo Fisher & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Thermo Fisher (TMO) and PayPal (PYPL).
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
Here's Why You Should Hold on to Pacific Biosciences Stock
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Thermo Fisher (TMO) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?
by Zacks Equity Research
Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.
Canopy Growth (CGC) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.